Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Serum Macrophage Migration Inhibitory Factor as a Biomarker of Active Pulmonary Tuberculosis

  • Shang, Zhong-bo (Department of Clinical Laboratory, Wuxi Huishan People's Hospital) ;
  • Wang, Jun (Department of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University) ;
  • Kuai, Shou-gang (Department of Clinical Laboratory, Wuxi Huishan People's Hospital) ;
  • Zhang, Yin-yin (Department of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University) ;
  • Ou, Qin-fang (Department of Respiratory Medicine, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University) ;
  • Pei, Hao (Department of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University) ;
  • Huang, Li-hua (Department of Respiratory Medicine, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University)
  • Received : 2016.11.23
  • Accepted : 2017.09.20
  • Published : 2018.01.01
⟨ Previous Next ⟩

Abstract

Background: Macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine with chemokine-like functions, has been shown to play a central role in several acute and chronic inflammatory diseases. However, limited information is available regarding the use of MIF as an inflammatory pathway marker in patients with tuberculosis. This study aimed to investigate the association of MIF with $IFN-{\gamma}$ and $TNF-{\alpha}$ in active pulmonary tuberculosis (APTB) following anti-tuberculosis treatment. Methods: The MIF, $TNF-{\alpha}$, and $IFN-{\gamma}$ serum levels were determined in 47 patients with APTB by cytokine-specific ELISA at four phases: prior to anti-tuberculosis drug treatment (baseline), and following 2, 4, and 6 months of treatment. In addition, we measured the MIF, $TNF-{\alpha}$, and $IFN-{\gamma}$ serum levels in 50 health controls. Results: MIF serum levels were significantly elevated (P<0.05) in patients with APTB prior to treatment compared with that in control subjects, and $TNF-{\alpha}$ ${\geq}449.7pg/mL$ was associated with high MIF levels (${\geq}13.1ng/mL$). MIF levels were significantly reduced (P<0.01) following 2, 4, and 6 months of treatment, with variations in $TNF-{\alpha}$ and $IFN-{\gamma}$ serum levels. MIF levels were positively correlated with the paired $TNF-{\alpha}$ level at baseline (r=0.1103, P=0.0316) and following 6 months of treatment (r=0.09569, P=0.0364). Conclusions: A reduction in the MIF serum levels in patients with APTB following anti-tuberculosis treatment may positively affect host immune protection against Mycobacterium tuberculosis infection. Thus, serum MIF levels may constitute a useful marker for assessing therapy effectiveness in patients with APTB.

Keywords

Acknowledgement

Supported by : Wuxi Administration of Science & Technology, Wuxi Healthy Bureau

References

  1. Calandra T and Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003;3:791-800. https://doi.org/10.1038/nri1200
  2. Gregory JL, Morand EF, Mckeown SJ, Ralph JA, Hall P, Yang YH, et al. Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 2006;177:8072-79. https://doi.org/10.4049/jimmunol.177.11.8072
  3. Tillmann S, Bernhagen J, Noels H. Arrest functions of the MIF ligand/receptor axes in atherogenesis. Front Immunol 2013;4:115.
  4. Santos LL and Morand EF. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 2013;399:1-7.
  5. Morand EF, Leech M, Bemhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006;5: 399-410. https://doi.org/10.1038/nrd2029
  6. Baugh JA and Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2002;30:S27-35. https://doi.org/10.1097/00003246-200201001-00004
  7. Lolis E and Bucala R. Macrophage migration inhibitory factor. Expert Opin Ther Targets 2003;7:153-64. https://doi.org/10.1517/14728222.7.2.153
  8. Leng L and Bucala R. Macrophage migration inhibitory factor. Critical Care Med 2005;33:S475-77. https://doi.org/10.1097/01.CCM.0000191278.04636.D8
  9. Coban N, Onat A, Yildirim O, Can G, Erginelunaltuna N. Oxidative stress-mediated (sex-specific) loss of protection against type-2 diabetes by macrophage migration inhibitory factor (MIF)-173G/C polymorphism. Clin Chim Acta 2015;438:1-6. https://doi.org/10.1016/j.cca.2014.07.037
  10. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71. https://doi.org/10.1038/377068a0
  11. Awandare GA, Martinson JJ, Were T, Ouma C, Davenport GC, Ong'echa JM, et al. MIF (macrophage migration inhibitory factor) promoter polymorphism and susceptibility to severe malarial anemia. J Infect Dis 2009; 200:629-37. https://doi.org/10.1086/600894
  12. Yende S, Angus DC, Kong L, Kellum JA, Weissfeld L, Ferrell R, et al. The influence of macrophage migration inhibitory factor gene polymorphism on outcome from community-acquired pneumonia. FASEB J 2009;23: 2403-11. https://doi.org/10.1096/fj.09-129445
  13. Renner P, Roger T, Bochud PY, Sprong T, Sweep FC, Bochud M, et al. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J 2012;26:907-16. https://doi.org/10.1096/fj.11-195065
  14. Cooper AM and Khader SA. The role of cytokines in the initiation, expansion,and control of cellular immunity to tuberculosis. Immunol Rev 2008; 226:191-204. https://doi.org/10.1111/j.1600-065X.2008.00702.x
  15. Ameglio F, Casarini M, Capoluongo E, Mattia P, Puglisi G, Giosue S. Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis. Int J Tuberc Lung Dis 2005;9:98-104.
  16. Munk ME and Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J 1995;20:668-75.
  17. Boom WH, Canaday DH, Fulton SA, Gehring AJ, Rojas RE, Torres M. Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis 2003;83:98-106. https://doi.org/10.1016/S1472-9792(02)00054-9
  18. Denis M. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol 1991;132:150-7. https://doi.org/10.1016/0008-8749(91)90014-3
  19. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004;119:753-66. https://doi.org/10.1016/j.cell.2004.11.038
  20. Jacobs M, Brown N, Allie N, Rvffel B. Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha -deficient mice. Clin Immunol 2000;94:192-99. https://doi.org/10.1006/clim.2000.4835
  21. Van CR, Ottenhoff TH, Vander Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev 2002;15:294-309. https://doi.org/10.1128/CMR.15.2.294-309.2002
  22. White DA, Fang L, Chan W, Morand EF, Kiriazis H, Duffy SJ, et al. Pro-inflammatory action of MIF in acute myocardial infarction via activation of peripheral blood mononuclear cells. PloS One 2013;8:e76206. https://doi.org/10.1371/journal.pone.0076206
  23. Llamas-Covarrubias MA, Valle Y, Bucala R, Navarro-Hernandez RE, Palafox-Sanchez CA, Padilla-Gutierrez JR, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine 2013;61:759-65. https://doi.org/10.1016/j.cyto.2012.12.032
  24. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52. https://doi.org/10.1146/annurev.iy.10.040192.002211
  25. Pasparakis M, Alexopoulou L, Douni E, Kollias G. Tumour necrosis factors in immune regulation: everything that's interesting is. . .new! Cytokine Growth Factor Rev 1996;7:223-29. https://doi.org/10.1016/S1359-6101(96)00031-7
  26. Flynn JL and Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129. https://doi.org/10.1146/annurev.immunol.19.1.93
  27. Berry MP, Graham CM, McNab FW, Bioch SA, Oni T, Wilkinson KA, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-77. https://doi.org/10.1038/nature09247
  28. Bean AG, Roach DR, Briscoe H, France MP, Korner H, SedqwicK JD, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999;162:3504-11.
  29. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, Kirschner DE, et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008;76:916-26. https://doi.org/10.1128/IAI.01011-07
  30. Roach DR, Briscoe H, Saunders B, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-${\alpha}$ is essential for the control of an intracellular bacterial infection. J Exp Med 2001;193:239-46. https://doi.org/10.1084/jem.193.2.239
  31. Botha T and Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003;171:3110-8. https://doi.org/10.4049/jimmunol.171.6.3110
  32. Mohan VP, Scanga CA, Yu K, Scottd HM, Tanaka KE, Tsanq E, et al. Effects of tumor necrosis factor ${\alpha}$ on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-55. https://doi.org/10.1128/IAI.69.3.1847-1855.2001
  33. Smith SM, Klein MR, Malin AS, Sillah J, Mcadam KP, Dockrell HM, et al. Decreased IFN-gamma and increased IL-4 production by human CD8(+) T cells in response to Mycobacterium tuberculosis in tuberculosis patients. Tuberculosis 2002;82:7-13. https://doi.org/10.1054/tube.2001.0317
  34. Sharma S, Sharma M, Roy S, Kumar P, Bose M. Mycobacterium tuberculosis induces high production of nitric oxide in coordination with production of tumor necrosis factor-alpha in patients with fresh active tuberculosis but not in MDR tuberculosis. Immunol Cell Biol 2004;82: 377-82. https://doi.org/10.1111/j.0818-9641.2004.01245.x

Cited by

  1. Genetic Variants of the MIF Gene and Susceptibility of Rectal Cancer vol.14, pp.None, 2018, https://doi.org/10.2147/pgpm.s282653
  2. Host biomarkers for monitoring therapeutic response in extrapulmonary tuberculosis vol.142, pp.None, 2021, https://doi.org/10.1016/j.cyto.2021.155499